What is it about?
This article provides an overview of the SARS-CoV-2 variant Omicron (B.1.1.529) by reviewing the literature from major scientific databases. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, Omicron (B.1.1.529), was first reported to World Health Organization from South Africa on November 24, 2021. Omicron has been labeled a variant of concern because of genetic changes that increase transmissibility and decrease the effectiveness of health measures, vaccines, and therapeutics. This variant has 32 mutations in the spike protein, which is problematic because vaccinations designed to prevent SARS-CoV-2 infections target spike proteins. Despite some evidence that vaccination alone may not be enough, nonpharmaceutical practices such as continued use of face masks, proper hygiene precautions, and social distancing is required to combat this variant successfully.
Featured Image
Photo by Volodymyr Hryshchenko on Unsplash
Why is it important?
Omicron, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant that is now spreading across the world, is the most altered version to emerge so far, with mutations comparable to changes reported in earlier variants of concern linked with increased transmissibility and partial resistance to vaccine-induced immunity.
Perspectives
Although clear immunological and clinical data are not yet available, we extrapolated from what is known about mutations present in the Omicron variant of SARS-CoV-2 and offer preliminary indications on transmissibility, severity, and immune escape through existing research and databases.
Dr Adekunle Sanyaolu
Read the Original
This page is a summary of: SARS-CoV-2 Omicron variant (B.1.1.529): A concern with immune escape, World Journal of Virology, May 2022, Baishideng Publishing Group Co., Limited (formerly WJG Press),
DOI: 10.5501/wjv.v11.i3.137.
You can read the full text:
Resources
Contributors
The following have contributed to this page
